A Randomized, Double-Blind, Crossover, Pilot Study to Evaluate the Safety and Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, in Reducing Craving for a Cigarette in Daily Smokers
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Star Scientific, Inc
- Enrollment
- 111
- Locations
- 2
- Primary Endpoint
- Effectiveness of Ariva® Silver Wintergreen lozenge on reducing craving for a cigarette in daily smokers
Study Overview
Brief Summary
Study to determine the safety and effectiveness of Ariva® Silver Wintergreen lozenge on reducing craving for a cigarette in daily smokers.
Detailed Description
Each subject will be given an Ariva® Silver Wintergreen lozenge or a Silver Wintergreen lozenge, which contains only silver salt, on a random basis.
Once the lozenge has dissolved in the mouth, subjects will smoke one of their own cigarettes, and will answer questions about the experience and their craving for a cigarette.
After a washout period, each subject will repeat the steps with the second type of lozenge.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 23 Years to 72 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •healthy adult smoker
- •smoking for at least 5 years
- •smoking at least one (1) pack of cigarettes a day
- •interest in quitting smoking
Exclusion Criteria
- •known allergy to silver or silver salts
- •pregnant or breast-feeding
- •current drug or alcohol abuse, and/or history of drug or alcohol dependence within 3 months of study
Outcomes
Primary Outcomes
Effectiveness of Ariva® Silver Wintergreen lozenge on reducing craving for a cigarette in daily smokers
Time Frame: 90 minutes
Effectiveness to be measured by the change in score on a craving questionnaire, from before to after product use.
Secondary Outcomes
No secondary outcomes reported